Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 25:8:339.
doi: 10.3389/fped.2020.00339. eCollection 2020.

Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

Silvia Tenembaum  1 , E Ann Yeh  2 ; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC)
Collaborators, Affiliations
Review

Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

Silvia Tenembaum et al. Front Pediatr. .

Erratum in

Abstract

Neuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory demyelinating disease of the central nervous system (CNS) primarily affecting the optic nerves and spinal cord, but also involving other regions of the CNS including the area postrema, periaqueductal gray matter, and hypothalamus. Knowledge related to pediatric manifestations of NMOSD has grown in recent years, particularly in light of newer information regarding the importance of not only antibodies to aquaporin 4 (AQP4-IgG) but also myelin oligodendrocyte glycoprotein (MOG-IgG) in children manifesting clinically with this syndrome. In this review, we describe the current state of the knowledge related to clinical manifestations, diagnosis, and chronic therapies for children with NMOSD, with emphasis on literature that has been published in the last 5 years. Following the review, we propose recommendations for the assessment/follow up clinical care, and treatment of this population.

Keywords: MOG; NMOSD; diagnosis; neuroinflammation; pediatric; treatment.

PubMed Disclaimer

References

    1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. (2004) 364:2106–12. 10.1016/S0140-6736(04)17551-X - DOI - PubMed
    1. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. . MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Dis. (2018) 25:66–72. 10.1016/j.msard.2018.07.025 - DOI - PubMed
    1. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurology. (2015) 2:e62. 10.1212/NXI.0000000000000062 - DOI - PMC - PubMed
    1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. (1999) 53:1107–1114. 10.1212/WNL.53.5.1107 - DOI - PubMed
    1. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. (2015) 85:177–89. 10.1212/WNL.0000000000001729 - DOI - PMC - PubMed

LinkOut - more resources